Department of Medicine, Temple University School of Medicine, Philadelphia, USA.
J Neurogastroenterol Motil. 2010 Jul;16(3):232-42. doi: 10.5056/jnm.2010.16.3.232. Epub 2010 Jul 27.
Achalasia is an esophageal motility disorder of unknown cause, characterized by aperistalsis of the esophageal body and impaired lower esophageal sphincter relaxation. Patients present at all ages, primarily with dysphagia for solids/liquids and bland regurgitation. The diagnosis is suggested by barium esophagram and confirmed by esophageal manometry. Achalasia cannot be cured. Instead, our goal is to relieve symptoms, improve esophageal emptying and prevent the development of megaesophagus. The most successful therapies are pneumatic dilation and surgical myotomy. The overall success rate of graded pneumatic dilation is 78%, with women and older patients responding best. Laparoscopic myotomy, usually combined with a partial fundoplication, has an overall success rate of 87%. Young patients, especially men, are the best candidates for surgical myotomy. Botulinum toxin injection into the lower esophageal sphincter and smooth muscle relaxants are usually reserved for older patients or those with co-morbid illness. The prognosis for achalasia patients to return to near normal swallowing is good, but the disease is rarely "cured" with a single procedure and intermittent touch-up procedures may be required.
贲门失弛缓症是一种病因不明的食管动力障碍性疾病,其特征为食管体蠕动缺失和食管下括约肌松弛障碍。患者可在任何年龄段发病,主要表现为固体/液体吞咽困难和无味反流。该病通过食管钡餐造影检查提示,食管测压检查进一步确诊。贲门失弛缓症无法治愈,我们的治疗目标主要是缓解症状、改善食管排空并预防巨食管的发生。最有效的治疗方法为气囊扩张和手术肌切开术。分级气囊扩张的总成功率为 78%,女性和老年患者的反应最好。腹腔镜肌切开术,通常联合部分胃底折叠术,总成功率为 87%。年轻患者,尤其是男性,是手术肌切开术的最佳适应证。肉毒毒素注射到食管下括约肌和平滑肌松弛剂通常用于老年患者或合并疾病的患者。贲门失弛缓症患者恢复接近正常吞咽的预后良好,但很少有单一操作能“治愈”该疾病,可能需要间歇性的后续治疗。